KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals Reports Second Fiscal Quarter Results
- Preparing for Initiation of KVD900 Phase 3 Clinical Trial- - KVD824 Phase 2 KOMPLETE Clinical Trial Enrolling - - Funded Beyond Data on Both HAE Trials - KalVista Pharmaceuticals, Inc. (NASDAQ:
Source: finanznachrichten.de